Cancer therapy in mice using a pure population of CD8⁺ T cell specific to the AH1 tumor rejection antigen.

ABSTRACT: There is a growing interest in the use of patient-derived T cells for the treatment of various types of malignancies. The expansion of a polyclonal and polyspecific population of tumor-reactive T cells, with a subsequent infusion into the same donor patient, has been implemented, sometimes with positive results. It is not known, however, whether a set of T cells with a single antigen specificity may be sufficient for an effective therapy. To gain more insights in this matter, we used naturally occurring T cells recognizing a retroviral peptide (AH1), which is endogenous in many tumor cell lines of BALB/c origin and which serves as potent tumor rejection antigen. We were able to isolate and expand this rare population of T cells to numbers suitable for therapy experiments in mice (i.e., up

SUBMITTER: Stringhini M 

PROVIDER: S-EPMC8505334 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature